Humanigen Announces Participation and Presentation at Multiple Conferences in May
May 04 2022 - 7:00AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ announced today that
management will present and participate at multiple investors
conferences in May 2022. Details of the conferences are as
follows:
LSX World Congress
Tim Morris, COO & CFO, will provide an in-person corporate
presentation at 10:45am EDT in London at the LSX World Congress on
May 10, 2022. The presentation will only be available to those in
attendance at the meeting. Additionally, Tim Morris will
participate in a panel titled ‘Multi-Jurisdictional Drug
Development’ at 8:20am EDT on May 11, 2022. For more information,
please access the event website at
https://www.lsxleaders.com/lsx-world-congress.
H.C. Wainwright Global Investment Conference
Cameron Durrant, Chairman & CEO, will make a corporate
presentation at 11:00am EDT on May 24, 2022. A livestream will be
accessible via the link below and a webcast link to a recording of
the event will be posted to the “Events and Presentations” section
of Humanigen’s investor relations website after the event.
Webcast:
https://journey.ct.events/view/8e10da2e-d387-4ab0-97c2-fd6aec9fd7ef
The webcast will be available for 90 days under the “Events
& Presentations” section of the company’s website at
www.ir.humanigen.com
About Humanigen
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a
clinical-stage biopharmaceutical company focused on preventing and
treating an immune hyper-response called ‘cytokine storm’.
Lenzilumab is a first-in class antibody that binds to and
neutralizes granulocyte-macrophage colony-stimulating factor
(GM-CSF). Results from preclinical models indicate GM-CSF is an
upstream regulator of many inflammatory cytokines and chemokines
involved in the cytokine storm. Early in the COVID-19 pandemic,
investigation showed high levels of GM-CSF secreting T cells were
associated with disease severity and intensive care unit admission.
Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with
lenzilumab may prevent consequences of a full-blown cytokine storm
in hospitalized patients with COVID-19. Humanigen is developing
lenzilumab as a treatment for cytokine storm associated with
COVID-19 and CD19-targeted CAR-T cell therapies and is also
exploring the effectiveness of lenzilumab in other inflammatory
conditions such as acute Graft versus Host Disease in patients
undergoing allogeneic hematopoietic stem cell transplantation,
eosinophilic asthma, and rheumatoid arthritis. For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward- looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding our plans relating to
lenzilumab.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
our lack of profitability and need for additional capital to grow
our business; our dependence on partners to further the development
of our product candidates; the uncertainties inherent in the
development, attainment of the requisite regulatory authorizations
and approvals and launch of any new pharmaceutical product; the
outcome of pending or future litigation; and the various risks and
uncertainties described in the "Risk Factors" sections of our
latest annual and quarterly reports and other filings with the
SEC.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. We
undertake no obligation to revise or update any forward-looking
statements made in this presentation to reflect events or
circumstances after the date hereof, to reflect new information or
the occurrence of unanticipated events, to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, in each case, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504005441/en/
Humanigen Investor Relations Ken Trbovich Humanigen
trbo@humanigen.com 650-410-3206
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024